{"id":321731,"date":"2024-10-25T00:00:00","date_gmt":"2024-10-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0002-2024-biopharma-idiopathic-pulmonary-fibrosis-landscape-forecast-niche-rare-disease\/"},"modified":"2026-04-25T11:19:01","modified_gmt":"2026-04-25T11:19:01","slug":"nrlfim0002-2024-biopharma-idiopathic-pulmonary-fibrosis-landscape-forecast-niche-rare-disease-landscape-forecast-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0002-2024-biopharma-idiopathic-pulmonary-fibrosis-landscape-forecast-niche-rare-disease-landscape-forecast-us\/","title":{"rendered":"Idiopathic Pulmonary Fibrosis &#8211; Landscape &#038; Forecast &#8211; Niche &#038; Rare Disease Landscape &#038; Forecast (US\/EU5)"},"content":{"rendered":"<p>Idiopathic pulmonary fibrosis (<abbr title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>) is a chronic lung disorder characterized by an irreversible loss of lung function. Pirfenidone was the first disease-modifying therapy (<abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>) approved for <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>, followed soon after nintedanib (Ofev) by Boehringer Ingelheim. These therapies set the stage for fierce competition in the <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> therapy market. We explore this evolving space by examining current medical practice, including the clinical and commercial outlook for pirfenidone and nintedanib (Ofev); identifying the areas of pressing unmet need in the treatment of <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>; and assessing emerging therapies, including United Therapeutics\u2019 treprostinil (inhaled), Boehringer Ingelheim&#8217;s <abbr data-abbreviation-entity=\"5870\" title=\"orally\">PO<\/abbr>-administered BI-1015550, Bristol Myers Squibb&#8217;s <abbr data-abbreviation-entity=\"5870\" title=\"orally\">PO<\/abbr>-administered <abbr title=\"Bristol Myers Squibb\">BMS<\/abbr>-986278, and EmphyCorp&#8217;s N115 (sodium pyruvate).<\/p>\n<p><b>Questions answered<\/b><\/p>\n<ul class=\"round-bullets\">\n<li>How will the size of the <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> population change through 2033? How large are the key subpopulations? What percentage of the <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> population receives drug treatment?<\/li>\n<li>How do interviewed experts view the clinical profiles of pirfenidone and nintedanib (Ofev), and what factors drive or constrain their use? What are the most pressing clinical needs in the management of <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>, according to experts?<\/li>\n<li>Which emerging therapies do <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> experts consider most promising? If approved, how would emerging therapies influence the management of <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> and the market positions of pirfenidone and nintedanib (Ofev)? What is the commercial potential of treprostinil (inhaled), BI-1015550, <abbr title=\"Bristol Myers Squibb\">BMS<\/abbr>-986278, and N115 (sodium pyruvate)?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key feature<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-321731","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-idiopathic-pulmonary-fibrosis","biopharma-therapy-areas-respiratory","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/321731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":6,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/321731\/revisions"}],"predecessor-version":[{"id":575898,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/321731\/revisions\/575898"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=321731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}